MarketPulse

genetic medicines

3 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Calidi Biotherapeutics Raises $6M in Public Offering, Exercises Full Warrant Overallotment

Calidi Biotherapeutics closed a $6 million underwritten public offering, issuing 12.1 million shares and Series J, K, L warrants with $0.50 exercise prices.
CLDIwarrantspublic offering
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Calidi Biotherapeutics Launches Public Offering to Bolster Growth

Calidi Biotherapeutics launches underwritten public offering of common stock and warrants, with Ladenburg Thalmann managing the raise for working capital and corporate purposes.
CLDIwarrantspublic offering
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Beam Therapeutics to Unveil 2025 Results and Novel Liver Disease Program

Beam Therapeutics will discuss 2025 results and unveil a new liver disease program on February 24, 2026. The company also secured FDA alignment for accelerated approval of BEAM-302.
BEAMFDA approvalbase editing